NYC Skyline BW

DEALS

Cytovia

Cytovia

Open

Health Care, Immuno-Oncology

pre-IPO

Early-Stage Immuno-Oncology Company; Pre-IPO Bridge Round

$70mm

Raising

$30mm

$92.97bn by 2025

Global I/O TAM

10%

CAGR

Left In the Round

Backed By:

About Cytovia Therapeutics

Cytovia Therapeutics Inc is clinical stage biotechnology company that develops immunotherapies for several unmet medical needs in cancer and infectious diseases. The company has research partnerships with Cellectis, CytoImmune, STC Biologics, the New York Stem Cell Foundation (NYSCF), University of California San Francisco (UCSF), the National Cancer Institute (NCI) and the Hebrew University of Jerusalem.

Cytovia is led and backed by the TF Capital, the largest biotech VC in China, Jack Ma’s Yunfeng, and Biotrack. The Ligo Investor Network has been offered a special opportunity to participate in a bridge round prior to the public offering of a highly anticipated immuno-oncology (I/O) company, the details of which can be discussed with interested parties.

Partners: